Xinda BioAdam single anti-injection fluid has been approved by NMPA for two new adaptations

On December 23, Xinda Bio announced that its recombinant human anti-tumor necrotic cause - α (TNF-α) monoclonal antibody drug Surisin ® (Adamo monoantigen injection, English trademark: SULINNO®) was obtained NMPA approved two new adaptations for the treatment of plaque-like psoriasis in children and inadequate response to glucosal hormones, the need for the use of glucoticoids in moderation, or non-infectious intermediate glucitis, post-glucitis, and whole glucitis in adults who are not suitable for glucosticosteroid therapy.
this is the 5th ® 6th adaptive disease approved by Thessoud.
Surixin® was approved for the first time by NMPA on September 2, 2020, after previously approved adaptations were rheumatoid arthritis, strong straight spina bifida, psoriasis and multi-joint type of young idlytic arthritis.
Su Lixin ® a biosynthetic drug for the original drug Adamo monoantigen.
Since its launch, the original drug Adamo single anti-injection has been approved worldwide for the treatment of 17 diseases including rheumatoid arthritis, rheumatoid spina bifida, psoriasis (including plaque-like psoriasis in children), psoriasis arthritis, early-onset idiopathic arthritis, Crohn's disease (including crohn's disease in children), ulcerative colitis, psoriasis, and glucitis.
According to the announcement, the results of a head-to-head control study conducted in patients with severe spina bifida showed that Su Lixin ® and Shumeile® had similar clinical efficacy and safety, and their clinical findings were published in 2019 in the internationally renowned journal Lancet Rheumatology.
source: Xinda Bio enterprise announcement